Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Although poly (ADP-ribose) polymerase (PARP) inhibitors have been a great addition to the therapeutic options available for patients with ovarian cancer, additional therapies and therapeutic combinations are needed. Saravut (John) J. Weroha, M.D., Ph.D., hopes to use his translational research to develop those therapies for ovarian and other gynecological cancers.
As a medical oncologist treating recurrent and new gynecological cancers, Dr. Weroha sees patients who are asking questions, looking for cures and searching for hope. Through his research, he turns to science to find the answers, develop the cures and create hope for these patients. Dr. Weroha's research goal is to contribute to the knowledge that will improve current therapies and create new ones for patients with ovarian cancer and other gynecological malignancies.
Learn about clinical trials that address specific scientific questions about human health and disease.
See my studies.
Explore all research studies at Mayo Clinic.
See the peer-reviewed findings I have published as a result of my research.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.